Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First annual report of the Austrian CML registry.
Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. Schmidt S, et al. Among authors: fridrik m. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11. Wien Klin Wochenschr. 2010. PMID: 20936366
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Thaler J, et al. Among authors: fridrik m. Leuk Res. 1997 Jan;21(1):75-80. doi: 10.1016/s0145-2126(96)00084-7. Leuk Res. 1997. PMID: 9029189 Clinical Trial.
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J. Hilbe W, et al. Among authors: fridrik m. Leuk Res. 1998 Oct;22(10):881-6. doi: 10.1016/s0145-2126(98)00064-2. Leuk Res. 1998. PMID: 9766747
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Hilbe W, et al. Among authors: fridrik m. Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8. doi: 10.3109/10428190109097753. Leuk Lymphoma. 2001. PMID: 11911409 Clinical Trial.
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R. Fridrik MA, et al. Eur J Cancer. 2016 May;58:112-21. doi: 10.1016/j.ejca.2016.02.004. Epub 2016 Mar 15. Eur J Cancer. 2016. PMID: 26990931 Clinical Trial.
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. Kühr T, et al. Among authors: fridrik m. Leuk Res. 2003 May;27(5):405-11. doi: 10.1016/s0145-2126(02)00223-0. Leuk Res. 2003. PMID: 12620292 Clinical Trial.
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Greil R, et al. Among authors: fridrik m. Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16. Lancet Haematol. 2016. PMID: 27374465 Clinical Trial.
80 results